Proteomic remodeling of proteasome in right heart failure

Journal of Molecular and Cellular Cardiology

Volumn 66, Issue , 2014, Pages 41-52

  Fessart, Delphine ^a,b   Martin Negrier, Marie Laure ^c   Claverol, Stéphane ^a   Thiolat, Marie Laure ^c   Crevel, Huguette ^a,b   Toussaint, Christian ^a   Bonneu, Marc ^a   Muller, Bernard ^a,b   Savineau, Jean Pierre ^a,b   Delom, Frederic ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b CENTRE DE RECHERCHE CARDIO THORACIQUE DE BORDEAUX   (France)

^c INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

Author keywords

Proteasomal activities; Proteasome; Quantitative proteomic; Right heart failure; Ubiquitin

Indexed keywords

BINDING PROTEIN; CASPASE; CHYMOTRYPSIN; CYTOSKELETON PROTEIN; MESSENGER RNA; PROTEINASE; PROTEINASE INHIBITOR; PROTEOME; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOSKELETON; DISEASE MODEL; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; LIQUID CHROMATOGRAPHY; MALE; MICROTUBULE; MOLECULAR MECHANICS; MOTOR ACTIVITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEOMICS; RAT; TANDEM MASS SPECTROMETRY; UBIQUITINATION;

RATTUS;

PROTEASOMAL ACTIVITIES; PROTEASOME; QUANTITATIVE PROTEOMIC; RIGHT HEART FAILURE; UBIQUITIN;

ANIMALS; ANOXIA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEART FAILURE; HEART VENTRICLES; MALE; MONOCROTALINE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; PROTEOME; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; UBIQUITINATION; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 84888264654     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.10.015     Document Type: Article

References (56)

1. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000, 35:569-582.
2. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., Poole-Wilson P.A., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29:2388-2442.
3. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:e391-e479.
4. Markel T.A., Wairiuko G.M., Lahm T., Crisostomo P.R., Wang M., Herring C.M., et al. The right heart and its distinct mechanisms of development, function, and failure. J Surg Res 2008, 146:304-313.
5. Loscalzo J. Proteomics in cardiovascular biology and medicine. Circulation 2003, 108:380-383.
6. McGregor E., Dunn M.J. Proteomics of the heart: unraveling disease. Circ Res 2006, 98:309-321.
7. Stanley B.A., Gundry R.L., Cotter R.J., Van Eyk J.E. Heart disease, clinical proteomics and mass spectrometry. Dis Markers 2004, 20:167-178.
8. Redout E.M., van der Toorn A., Zuidwijk M.J., van de Kolk C.W., van Echteld C.J., Musters R.J., et al. Antioxidant treatment attenuates pulmonary arterial hypertension-induced heart failure. Am J Physiol Heart Circ Physiol 2010, 298:H1038-H1047.
9. de La Roque E.D., Thiaudiere E., Ducret T., Marthan R., Franconi J.M., Guibert C., et al. Effect of chronic hypoxia on pulmonary artery blood velocity in rats as assessed by electrocardiography-triggered three-dimensional time-resolved MR angiography. NMR Biomed 2010, 24:225-230.
10. Bonnet S., Belus A., Hyvelin J.M., Roux E., Marthan R., Savineau J.P. Effect of chronic hypoxia on agonist-induced tone and calcium signaling in rat pulmonary artery. Am J Physiol Lung Cell Mol Physiol 2001, 281:L193-L201.
11. Bonnet S., Hyvelin J.M., Bonnet P., Marthan R., Savineau J.P. Chronic hypoxia-induced spontaneous and rhythmic contractions in the rat main pulmonary artery. Am J Physiol Lung Cell Mol Physiol 2001, 281:L183-L192.
12. Lalich J.L., Johnson W.D., Raczniak T.J., Shumaker R.C. Fibrin thrombosis in monocrotaline pyrrole-induced cor pulmonale in rats. Arch Pathol Lab Med 1977, 101:69-73.
13. Meyrick B., Reid L. Development of pulmonary arterial changes in rats fed Crotalaria spectabilis. Am J Pathol 1979, 94:37-50.
14. Sugita T., Hyers T.M., Dauber I.M., Wagner W.W., McMurtry I.F., Reeves J.T. Lung vessel leak precedes right ventricular hypertrophy in monocrotaline-treated rats. J Appl Physiol 1983, 54:371-374.
15. Guignabert C., Raffestin B., Benferhat R., Raoul W., Zadigue P., Rideau D., et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005, 111:2812-2819.
16. Agard C., Rolli-Derkinderen M., Dumas-de-La-Roque E., Rio M., Sagan C., Savineau J.P., et al. Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension. Br J Pharmacol 2009, 158:1285-1294.
17. Stenmark K.R., Meyrick B., Galie N., Mooi W.J., McMurtry I.F. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009, 297:L1013-L1032.
18. van Suylen R.J., Smits J.F., Daemen M.J. Pulmonary artery remodeling differs in hypoxia- and monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med 1998, 157:1423-1428.
19. Kall L., Canterbury J.D., Weston J., Noble W.S., MacCoss M.J. Semi-supervised learning for peptide identification from shotgun proteomics datasets. Nat Methods 2007, 4:923-925.
20. Delom F., Fessart D., Chevet E. Regulation of calnexin sub-cellular localization modulates endoplasmic reticulum stress-induced apoptosis in MCF-7 cells. Apoptosis 2007, 12:293-305.
21. Berthet A., Bezard E., Porras G., Fasano S., Barroso-Chinea P., Dehay B., et al. L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor. J Neurosci 2012, 32:681-691.
22. Pickering A.M., Davies K.J. Degradation of damaged proteins: the main function of the 20S proteasome. Prog Mol Biol Transl Sci 2012, 109:227-248.
23. Li F., Zhang L., Craddock J., Bruce-Keller A.J., Dasuri K., Nguyen A., et al. Aging and dietary restriction effects on ubiquitination, sumoylation, and the proteasome in the heart. Mech Ageing Dev 2008, 129:515-521.
24. Kisselev A.F., Kaganovich D., Goldberg A.L. Binding of hydrophobic peptides to several non-catalytic sites promotes peptide hydrolysis by all active sites of 20S proteasomes. Evidence for peptide-induced channel opening in the alpha-rings. J Biol Chem 2002, 277:22260-22270.
25. Murata S., Yashiroda H., Tanaka K. Molecular mechanisms of proteasome assembly. Nat Rev Mol Cell Biol 2009, 10:104-115.
26. Fuertes G., Villarroya A., Knecht E. Role of proteasomes in the degradation of short-lived proteins in human fibroblasts under various growth conditions. Int J Biochem Cell Biol 2003, 35:651-664.
27. Rodgers K.J., Dean R.T. Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates. Int J Biochem Cell Biol 2003, 35:716-727.
28. Kim S.Y., Lee J.H., Huh J.W., Kim H.J., Park M.K., Ro J.Y., et al. Bortezomib alleviates experimental pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2012, 47:698-708.
29. Scholten A., Mohammed S., Low T.Y., Zanivan S., van Veen T.A., Delanghe B., et al. In-depth quantitative cardiac proteomics combining electron transfer dissociation and the metalloendopeptidase Lys-N with the SILAC mouse. Mol Cell Proteomics 2011, 10(O111):008474.
30. Kreymborg K., Uchida S., Gellert P., Schneider A., Boettger T., Voswinckel R., et al. Identification of right heart-enriched genes in a murine model of chronic outflow tract obstruction. J Mol Cell Cardiol 2010, 49:598-605.
31. Drews O., Wildgruber R., Zong C., Sukop U., Nissum M., Weber G., et al. Mammalian proteasome subpopulations with distinct molecular compositions and proteolytic activities. Mol Cell Proteomics 2007, 6:2021-2031.
32. Boncela J., Przygodzka P., Papiewska-Pajak I., Wyroba E., Osinska M., Cierniewski C.S. Plasminogen activator inhibitor type 1 interacts with alpha3 subunit of proteasome and modulates its activity. J Biol Chem 2011, 286:6820-6831.
33. Boncela J., Przygodzka P., Papiewska-Pajak I., Wyroba E., Cierniewski C.S. Association of plasminogen activator inhibitor type 2 (PAI-2) with proteasome within endothelial cells activated with inflammatory stimuli. J Biol Chem 2011, 286:43164-43171.
34. Kaab S., Barth A.S., Margerie D., Dugas M., Gebauer M., Zwermann L., et al. Global gene expression in human myocardium-oligonucleotide microarray analysis of regional diversity and transcriptional regulation in heart failure. J Mol Med (Berl) 2004, 82:308-316.
35. Hwang J.J., Allen P.D., Tseng G.C., Lam C.W., Fananapazir L., Dzau V.J., et al. Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiol Genomics 2002, 10:31-44.
36. Depre C., Powell S.R., Wang X. The role of the ubiquitin-proteasome pathway in cardiovascular disease. Cardiovasc Res 2010, 85:251-252.
37. Weekes J., Morrison K., Mullen A., Wait R., Barton P., Dunn M.J. Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics 2003, 3:208-216.
38. Tsukamoto O., Minamino T., Kitakaze M. Functional alterations of cardiac proteasomes under physiological and pathological conditions. Cardiovasc Res 2010, 85:339-346.
39. Rock K.L., Gramm C., Rothstein L., Clark K., Stein R., Dick L., et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78:761-771.
40. Baumeister W., Walz J., Zuhl F., Seemuller E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 1998, 92:367-380.
41. Chen P., Hochstrasser M. Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly. Cell 1996, 86:961-972.
42. Chu-Ping M., Vu J.H., Proske R.J., Slaughter C.A., DeMartino G.N. Identification, purification, and characterization of a high molecular weight, ATP-dependent activator (PA700) of the 20S proteasome. J Biol Chem 1994, 269:3539-3547.
43. 2+-free calmodulin and calmodulin damaged by in vitro aging are selectively degraded by 26S proteasomes without ubiquitination. J Biol Chem 2000, 275:20295-20301.
44. Powell S.R. The ubiquitin-proteasome system in cardiac physiology and pathology. Am J Physiol Heart Circ Physiol 2006, 291:H1-H19.
45. Wang X., Su H., Ranek M.J. Protein quality control and degradation in cardiomyocytes. J Mol Cell Cardiol 2008, 45:11-27.
46. Patterson C., Ike C., Willis PWt, Stouffer G.A., Willis M.S. The bitter end: the ubiquitin-proteasome system and cardiac dysfunction. Circulation 2007, 115:1456-1463.
47. Yu X., Kem D.C. Proteasome inhibition during myocardial infarction. Cardiovasc Res 2010, 85:312-320.
48. Mearini G., Schlossarek S., Willis M.S., Carrier L. The ubiquitin-proteasome system in cardiac dysfunction. Biochim Biophys Acta 2008, 1782:749-763.
49. Hedhli N., Depre C. Proteasome inhibitors and cardiac cell growth. Cardiovasc Res 2010, 85:321-329.
50. Drews O., Tsukamoto O., Liem D., Streicher J., Wang Y., Ping P. Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy. Circ Res 2010, 107:1094-1101.
51. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature 1997, 387:299-303.
52. Kostin S., Pool L., Elsasser A., Hein S., Drexler H.C., Arnon E., et al. Myocytes die by multiple mechanisms in failing human hearts. Circ Res 2003, 92:715-724.
53. Predmore J.M., Wang P., Davis F., Bartolone S., Westfall M.V., Dyke D.B., et al. Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. Circulation 2010, 121:997-1004.
54. Tsukamoto O., Minamino T., Okada K., Shintani Y., Takashima S., Kato H., et al. Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice. Biochem Biophys Res Commun 2006, 340:1125-1133.
55. Rajagopalan V., Zhao M., Reddy S., Fajardo G., Wang X., Dewey S., et al. Altered ubiquitin-proteasome signaling in right ventricular hypertrophy and failure. Am J Physiol Heart Circ Physiol 2013, 305:H551-H562.
56. Tiedemann R.E., Schmidt J., Keats J.J., Shi C.X., Zhu Y.X., Palmer S.E., et al. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood 2009, 113:4027-4037.